lockFact Sheet52-week results for Cosentyx® in hidradenitis suppurativa: A summary
Discover the data published in The Lancet on the long-term effect of Cosentyx® (secukinumab) in adults with hidradenitis suppurativa from the SUNRISE and SUNSHINE trials.
lockDisease Awareness / Fact SheetSpinal Muscular Atrophy
Understanding spinal muscular atrophy, a rare, neuromuscular genetic disease.
lockScience & Innovation / Fact SheetThe Novartis AAV Platform
Modified viruses – including adeno-associated viruses – are an efficient way to transport therapeutic genetic material to affected cells.
lockScience & Innovation / Fact SheetThe Novartis Gene Therapies Manufacturing Process
Manufacturing of gene therapy is complex. Novartis has developed a reproducible manufacturing process.
lockCorporate Responsibility / Fact SheetAbout Novartis Gene Therapies
Novartis Gene Therapies is the world leader in gene therapy, and is reimagining medicine to transform the lives of patients.
lockScience & Innovation / Fact SheetAbout Gene Therapy
Gene therapy – an innovative approach to treating rare, genetic diseases.
lockProducts / Fact SheetRTH258 Brolucizumab Clinical Trials
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.
lockProducts / Fact SheetKymriah® (tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice
Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US
lockProducts / Fact SheetThe JULIET Clinical Trial
The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.
lockProducts / Fact SheetHow does ACZ885 work?
ACZ885 is a human monoclonal antibody, which is a protein that is designed to bind to only one substance in the body. ACZ885 is designed to bind to human interleukin-1β (IL-1β).
lockProducts / Fact SheetErenumab (AMG 334) Key Clinical Trials By The Numbers
Erenumab has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficancy in migraine prevention.
lockProducts / Fact SheetAbout erenumab AMG 334
Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.